Trials / Completed
CompletedNCT04997148
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical Practice (CAMELOT-MS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 116 (actual)
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.
Conditions
Timeline
- Start date
- 2021-08-11
- Primary completion
- 2023-09-14
- Completion
- 2023-09-14
- First posted
- 2021-08-09
- Last updated
- 2024-12-18
- Results posted
- 2024-12-18
Locations
8 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04997148. Inclusion in this directory is not an endorsement.